Interleukin-4 - Amgen/Sanofi Winthrop
Latest Information Update: 24 Oct 2021
At a glance
- Originator Amgen
- Developer Amgen; Sanofi Winthrop
- Class Interleukins
- Mechanism of Action B cell stimulants; Immunosuppressants; Interleukin 4 receptor agonists; Mast cell stabilisers; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Graft-versus-host disease; Immunodeficiency disorders
Most Recent Events
- 19 Apr 1996 Discontinued-Unspecified phase for Immunodeficiency disorders in USA (Unknown route)
- 13 Dec 1995 Discontinued-Preclinical for Graft-versus-host disease in USA (Unknown route)
- 28 Sep 1995 Discontinued-II for Cancer in USA (IV)